Alphatec (NASDAQ:ATEC – Get Free Report) released its earnings results on Tuesday. The medical technology company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.01), Briefing.com reports. The firm had revenue of $138.48 million during the quarter, compared to the consensus estimate of $134.07 million. The firm’s revenue for the quarter was up 26.9% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.40) EPS.
Alphatec Trading Up 2.3 %
Shares of ATEC stock opened at $13.58 on Wednesday. Alphatec has a 1 year low of $8.66 and a 1 year high of $19.14. The firm has a fifty day moving average price of $13.32 and a 200-day moving average price of $13.56. The company has a market cap of $1.90 billion, a price-to-earnings ratio of -8.76 and a beta of 1.48. The company has a debt-to-equity ratio of 6.54, a current ratio of 2.86 and a quick ratio of 1.99.
Insider Buying and Selling at Alphatec
In other Alphatec news, General Counsel Tyson Eliot Marshall sold 11,825 shares of the firm’s stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $13.30, for a total transaction of $157,272.50. Following the sale, the general counsel now owns 305,095 shares in the company, valued at approximately $4,057,763.50. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In other news, General Counsel Tyson Eliot Marshall sold 11,825 shares of the business’s stock in a transaction on Friday, March 1st. The shares were sold at an average price of $13.30, for a total value of $157,272.50. Following the transaction, the general counsel now owns 305,095 shares of the company’s stock, valued at $4,057,763.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, EVP David Sponsel sold 2,500 shares of the firm’s stock in a transaction on Wednesday, February 14th. The shares were sold at an average price of $16.16, for a total transaction of $40,400.00. Following the transaction, the executive vice president now directly owns 637,418 shares of the company’s stock, valued at $10,300,674.88. The disclosure for this sale can be found here. Over the last quarter, insiders sold 285,069 shares of company stock valued at $3,971,495. Company insiders own 29.12% of the company’s stock.
Wall Street Analyst Weigh In
About Alphatec
Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.
Featured Articles
- Five stocks we like better than Alphatec
- What Are Dividend Champions? How to Invest in the Champions
- Celsius Stock’s Post-Earnings Morning Dip, Better than Coffee
- What to Know About Investing in Penny Stocks
- Chegg Chokes on AI Attempt, CEO Talks it Up As He Passes Torch
- Investing in Travel Stocks Benefits
- Does Logitech’s EPS Beat Signal the Rebound of Video Gaming?
Receive News & Ratings for Alphatec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alphatec and related companies with MarketBeat.com's FREE daily email newsletter.